Trial Profile
Phase III trial of dronedarone/ranolazine in patients with atrial fibrillation
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 26 May 2014
Price :
$35
*
At a glance
- Drugs Dronedarone/ranolazine (Primary)
- Indications Atrial fibrillation
- Focus Registrational; Therapeutic Use
- 26 May 2014 New trial record
- 10 May 2014 Gilead is planning this phase III trial assessing a fixed-dose combination (FDC) of ranolazine and low-dose dronedarone for paroxysmal or persistent (non-permanent) atrial fibrillation, according to a media release.